Hodi et al. reported immune-mediated vascular damage in biopsies analyzed from advanced melanoma cancer patients who were treated with CTLA-4 blocking antibody infusion accompanied by tumor necrosis[51], highlighting the potential effect of CTLA-4 immune checkpoint inhibition on angiogenesis in the TME. The gene discussed is CTLA4; the disease is neoplasm.